|
WO2010091396A2
|
|
Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
|
|
US2011275701A1
|
|
Anti-thrombin aptamer formulations and methods for use
|
|
WO2009140383A2
|
|
Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics
|
|
WO2009126632A1
|
|
Compositions and methods for the use of mutant t3 rna polymerases in the synthesis of modified nucleic acid transcripts
|
|
WO2009073820A2
|
|
Biopolymer-nucleic acid conjugation
|
|
WO2009014705A1
|
|
Compositions and methods for in vivo selex
|
|
WO2008150495A2
|
|
vWF APTAMER FORMULATIONS AND METHODS FOR USE
|
|
WO2008134077A1
|
|
Metabolic profile directed aptamer medicinal chemistry
|
|
CA2673029A1
|
|
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
WO2007126941A2
|
|
Solid support reagents for synthesis
|
|
ZA200807620B
|
|
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
EP1933882A2
|
|
Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
|
|
WO2007025049A2
|
|
Aptamers that bind thrombin with high affinity
|
|
CN101501056A
|
|
Aptamers that bind thrombin with high affinity
|
|
AU2006265898A1
|
|
Polynucleotides and polypeptides of the IL-12 family of cytokines
|
|
MX2007016561A
|
|
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts.
|
|
WO2006096754A2
|
|
Stabilized aptamers to psma and their use as prostate cancer therapeutics
|
|
US2007041901A1
|
|
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
EP1807107A2
|
|
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CN101356284A
|
|
Aptamer medicinal chemistry
|
